Lynn Canavan, PhD
About Lynn Canavan, PhD
Lynn Canavan, PhD, is a Regulatory Project Manager at Boston Scientific with extensive experience in regulatory affairs and biomedical science.
Current Role at Boston Scientific
Lynn Canavan currently serves as a Regulatory Project Manager at Boston Scientific. She stepped into this role in 2021. In this capacity, Lynn oversees regulatory projects, ensuring compliance with relevant standards and regulations. Her role involves extensive collaboration with cross-functional teams to manage regulatory submissions and approvals.
Previous Positions at Boston Scientific
Prior to her current role, Lynn Canavan held multiple positions at Boston Scientific, showcasing a broad range of expertise in regulatory affairs. From 2018 to 2021, she was the Principal Regulatory Affairs Specialist. Between 2015 and 2018, she worked as a Senior Regulatory Affairs Specialist. From 2013 to 2015, she took on the role of Regulatory Affairs Specialist. Additionally, Lynn spent five years, from 2008 to 2013, working as a Design Assurance Engineer in Galway.
Experience at BioVex (Amgen)
Before her extensive tenure at Boston Scientific, Lynn Canavan worked at BioVex (Amgen) as a Development Scientist from 2007 to 2008. Based in Oxford, United Kingdom, her responsibilities included developing innovative biopharmaceutical products. This role helped her gain significant insight into the field of biomedical research and development.
Role at Henkel (Loctite)
Lynn Canavan's early career included a role as Biomedical R&D Technician at Henkel (Loctite) in Dublin from 2002 to 2003. During her time at Henkel, she contributed to research and development in the realm of biomedical applications, which provided foundational experience for her later positions in regulatory affairs and project management.
Educational Background
Lynn Canavan holds a PhD in Biochemistry from the National University of Ireland, Galway. Her doctoral research, conducted from 2003 to 2007, focused on the genetic and biochemical analysis of the DNA damage response protein ATR. Prior to her PhD, she completed a Bachelor of Science (Hons) in Biomedical Science at the same institution, graduating in 2002.